Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02777931 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD
A Phase 2 study of Attention Deficit Disorder With Hyperactivity, sponsored by Aevi Genomic Medicine, LLC, a Cerecor company.
- Completed
- Registry status
- Phase 2
- Development phase
- 101
- Enrollment target
- 1
- Study location
NCT02777931 is a Phase 2 study of Attention Deficit Disorder With Hyperactivity that has completed, run by Aevi Genomic Medicine, LLC, a Cerecor company. The registered enrollment target is 101 participants, below the 350-participant average among 20 other Attention Deficit Disorder With Hyperactivity trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02777931, a Phase 2 study of Attention Deficit Disorder With Hyperactivity, has completed, sponsored by Aevi Genomic Medicine, LLC, a Cerecor company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 101 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, double-blind, placebo-controlled, parallel-group study of NFC-1 versus placebo in adolescents with ADHD who have genetic disorders impacting mGluRs.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG NFC-1
Study Locations (1)
Maryland
- The Clinical Trials Center at Kennedy Krieger Institute - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2016-06 |
| Est. Completion | 2017-02-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02777931
The ClinicalTrials.gov registry entry for NCT02777931 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 350-participant average among 20 other Attention Deficit Disorder With Hyperactivity trials with a reported enrollment target (71% lower). The listed sponsor is Aevi Genomic Medicine, LLC, a Cerecor company, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Attention Deficit Disorder With Hyperactivity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02777931 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT02777931 about?
NCT02777931 is a clinical study titled "Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD". This is a randomized, double-blind, placebo-controlled, parallel-group study of NFC-1 versus placebo in adolescents with ADHD who have genetic disorders impacting mGluRs.
What is the current status of trial NCT02777931?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 2016-06. Estimated completion is 2017-02-17.
What conditions does trial NCT02777931 study?
This clinical trial studies the following conditions: Attention Deficit Disorder With Hyperactivity.
What interventions are being tested in trial NCT02777931?
The interventions under investigation include: Placebo (DRUG), NFC-1 (DRUG).
Who is sponsoring clinical trial NCT02777931?
This trial is sponsored by Aevi Genomic Medicine, LLC, a Cerecor company, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02777931 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Disorder With Hyperactivity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
COMPLETED · Phase 2
-
Classroom Study to Assess Efficacy and Safety of MTS in Pediatric Patients Aged 6-12 With ADHD
COMPLETED · Phase 2
-
Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children
COMPLETED · Phase 2
-
Home-based Transcranial Direct Current Stimulation (tDCS) for Treatment of Attention-deficit/Hyperactivity Disorder (ADHD)
RECRUITING · NA
-
Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers
ACTIVE NOT RECRUITING
-
Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD)
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.